Total Payments
$37,250
2024 Payments
$27,082
Companies
55
Transactions
741
Medicare Patients
15,226
Medicare Billing
$691,883
Payment Breakdown by Category
Research$15,955 (42.8%)
Education$9,712 (26.1%)
Food & Beverage$8,700 (23.4%)
Travel$2,883 (7.7%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $15,955 | 17 | 42.8% |
| Education | $9,712 | 9 | 26.1% |
| Food and Beverage | $8,700 | 698 | 23.4% |
| Travel and Lodging | $2,883 | 17 | 7.7% |
Payments by Type
General
$21,295
724 transactions
Research
$15,955
17 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Eli Lilly and Company | $14,154 | 4 | $0 (2024) |
| INTUITIVE SURGICAL, INC. | $11,833 | 23 | $0 (2024) |
| Novo Nordisk Inc | $1,766 | 172 | $0 (2024) |
| Regeneron Pharmaceuticals, Inc. | $1,529 | 10 | $0 (2024) |
| PFIZER INC. | $1,227 | 120 | $0 (2024) |
| ConvaTec Inc. | $915.97 | 5 | $0 (2024) |
| Amgen Inc. | $827.07 | 51 | $0 (2024) |
| Astellas Pharma US Inc | $474.99 | 28 | $0 (2023) |
| SANOFI-AVENTIS U.S. LLC | $354.42 | 28 | $0 (2020) |
| Janssen Pharmaceuticals, Inc | $323.34 | 19 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $27,082 | 70 | Eli Lilly and Company ($12,370) |
| 2023 | $2,271 | 35 | Eli Lilly and Company ($1,784) |
| 2022 | $533.43 | 55 | Novo Nordisk Inc ($321.98) |
| 2021 | $433.14 | 39 | Novo Nordisk Inc ($325.07) |
| 2020 | $393.77 | 30 | PFIZER INC. ($90.68) |
| 2019 | $1,766 | 146 | Amgen Inc. ($278.23) |
| 2018 | $2,318 | 186 | Amgen Inc. ($344.93) |
| 2017 | $2,453 | 180 | Boehringer Ingelheim b.v. ($271.93) |
All Payment Transactions
741 individual payment records from CMS Open Payments — Page 1 of 30
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/09/2024 | Novo Nordisk Inc | Wegovy (Drug) | Food and Beverage | In-kind items and services | $13.05 | General |
| Category: Obesity | ||||||
| 12/05/2024 | Amgen Inc. | EVENITY (Biological), Prolia | Food and Beverage | In-kind items and services | $16.91 | General |
| Category: Bone Health | ||||||
| 12/02/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $11.65 | General |
| Category: Diabetes | ||||||
| 11/12/2024 | PFIZER INC. | ELIQUIS (Drug), NURTEC ODT | Food and Beverage | In-kind items and services | $12.13 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
| 11/12/2024 | Novo Nordisk Inc | Wegovy (Drug) | Food and Beverage | In-kind items and services | $1.50 | General |
| Category: Obesity | ||||||
| 11/04/2024 | Novo Nordisk Inc | Rybelsus (Drug), Ozempic | Food and Beverage | In-kind items and services | $11.94 | General |
| Category: Diabetes | ||||||
| 10/21/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $11.56 | General |
| Category: Diabetes | ||||||
| 10/18/2024 | PFIZER INC. | PREVNAR 20 (Biological), COMIRNATY, ABRYSVO | Food and Beverage | In-kind items and services | $21.14 | General |
| Category: VACCINES | ||||||
| 10/07/2024 | Novo Nordisk Inc | Wegovy (Drug) | Food and Beverage | In-kind items and services | $13.34 | General |
| Category: Obesity | ||||||
| 10/03/2024 | Merck Sharp & Dohme LLC | GARDASIL (Biological), CAPVAXIVE, GARDASIL 9 | Food and Beverage | In-kind items and services | $18.99 | General |
| Category: VACCINE | ||||||
| 09/26/2024 | Lilly USA, LLC | ZEPBOUND (Drug) | Food and Beverage | In-kind items and services | $17.92 | General |
| Category: Obesity | ||||||
| 09/25/2024 | INTUITIVE SURGICAL, INC. | Da Vinci Surgical System (Device) | Travel and Lodging | In-kind items and services | $231.86 | General |
| Category: SURGERY | ||||||
| 09/24/2024 | Eli Lilly and Company | — | — | Cash or cash equivalent | $12,275.00 | Research |
| Study: A STUDY OF DAILY ORAL ORFORGLIPRON (LY3502970) COMPARED WITH INSULIN GLARGINE IN PARTICIPANTS WITH TYPE 2 DIABETES AND OBESITY OR OVERWEIGHT AT INCREASED CARDIOVASCULAR RISK (ACHIEVE-4) | ||||||
| 09/24/2024 | INTUITIVE SURGICAL, INC. | DAVINCI XI (Device) | Education | In-kind items and services | $1,000.00 | General |
| Category: SURGERY | ||||||
| 09/24/2024 | INTUITIVE SURGICAL, INC. | Da Vinci Surgical System (Device) | Travel and Lodging | In-kind items and services | $143.00 | General |
| Category: SURGERY | ||||||
| 09/24/2024 | INTUITIVE SURGICAL, INC. | Da Vinci Surgical System (Device) | Travel and Lodging | In-kind items and services | $143.00 | General |
| Category: SURGERY | ||||||
| 09/24/2024 | INTUITIVE SURGICAL, INC. | Da Vinci Surgical System (Device) | Food and Beverage | In-kind items and services | $28.98 | General |
| Category: SURGERY | ||||||
| 09/18/2024 | INTUITIVE SURGICAL, INC. | Da Vinci Surgical System (Device) | Travel and Lodging | In-kind items and services | $30.00 | General |
| Category: SURGERY | ||||||
| 09/09/2024 | Novo Nordisk Inc | Rybelsus (Drug), Ozempic | Food and Beverage | In-kind items and services | $10.92 | General |
| Category: Diabetes | ||||||
| 09/05/2024 | Neurelis, Inc. | VALTOCO (Drug) | Food and Beverage | In-kind items and services | $19.24 | General |
| Category: EPILEPSY | ||||||
| 09/03/2024 | Novo Nordisk Inc | Wegovy (Drug) | Food and Beverage | In-kind items and services | $2.71 | General |
| Category: Obesity | ||||||
| 08/14/2024 | INTUITIVE SURGICAL, INC. | Da Vinci Surgical System (Device) | Travel and Lodging | In-kind items and services | $281.84 | General |
| Category: SURGERY | ||||||
| 08/14/2024 | INTUITIVE SURGICAL, INC. | Da Vinci Surgical System (Device) | Travel and Lodging | In-kind items and services | $19.00 | General |
| Category: SURGERY | ||||||
| 08/12/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $11.86 | General |
| Category: Diabetes | ||||||
| 08/06/2024 | PFIZER INC. | ELIQUIS (Drug), NURTEC ODT | Food and Beverage | In-kind items and services | $15.81 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A STUDY OF DAILY ORAL ORFORGLIPRON (LY3502970) COMPARED WITH INSULIN GLARGINE IN PARTICIPANTS WITH TYPE 2 DIABETES AND OBESITY OR OVERWEIGHT AT INCREASED CARDIOVASCULAR RISK (ACHIEVE-4) | Eli Lilly and Company | $13,159 | 3 |
| A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity | Regeneron Pharmaceuticals, Inc. | $1,529 | 10 |
| A PHASE 3 RANDOMIZED OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL LY3502970 COMPARED WITH ORAL SEMAGLUTIDE IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH METFORMIN (ACHIEVE-3) | Eli Lilly and Company | $995.02 | 1 |
| safety and efficacy linagliptin vs SU | Boehringer Ingelheim b.v. | $271.93 | 3 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 53 | 3,566 | 6,657 | $357,630 | $143,072 |
| 2022 | 57 | 3,709 | 6,101 | $403,389 | $168,562 |
| 2021 | 64 | 3,921 | 6,386 | $419,520 | $171,025 |
| 2020 | 60 | 4,030 | 9,151 | $520,716 | $209,223 |
Total Patients
15,226
Total Services
28,295
Medicare Billing
$691,883
Procedure Codes
234
All Medicare Procedures & Services
234 procedure records from CMS Medicare Utilization — Page 1 of 10
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2023 | 226 | 226 | $38,420 | $28,123 | 73.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 185 | 328 | $54,911 | $25,646 | 46.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 184 | 286 | $32,954 | $16,542 | 50.2% |
| 90662 | Influenza vaccine split virus, preservative free | Office | 2023 | 103 | 103 | $8,464 | $7,327 | 86.6% |
| 99496 | Transitional care management services for problem of high complexity | Office | 2023 | 22 | 30 | $10,830 | $6,396 | 59.1% |
| 80061 | Blood test, lipids (cholesterol and triglycerides) | Office | 2023 | 256 | 436 | $25,288 | $5,598 | 22.1% |
| 90677 | Pneumococcal conjugate vaccine, 20 valent (pcv20), for intramuscular use | Office | 2023 | 19 | 19 | $6,650 | $5,360 | 80.6% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2023 | 261 | 485 | $26,190 | $4,953 | 18.9% |
| 77067 | Screening mammography | Office | 2023 | 52 | 52 | $13,884 | $4,447 | 32.0% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 253 | 499 | $4,990 | $4,167 | 83.5% |
| G0444 | Annual depression screening, 5 to 15 minutes | Office | 2023 | 225 | 225 | $7,875 | $3,949 | 50.2% |
| G0008 | Administration of influenza virus vaccine | Office | 2023 | 111 | 111 | $4,995 | $3,238 | 64.8% |
| 83036 | Hemoglobin a1c level | Office | 2023 | 143 | 295 | $13,570 | $2,771 | 20.4% |
| 85027 | Complete blood cell count (red cells, white blood cell, platelets), automated test | Office | 2023 | 231 | 377 | $10,179 | $2,357 | 23.2% |
| 84443 | Blood test, thyroid stimulating hormone (tsh) | Office | 2023 | 119 | 143 | $10,010 | $2,354 | 23.5% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 89 | 248 | $12,152 | $2,300 | 18.9% |
| 87428 | Detection test by immunoassay technique for severe acute respiratory syndrome coronavirus and influenza | Office | 2023 | 32 | 35 | $4,900 | $1,450 | 29.6% |
| 82044 | Urine microalbumin (protein) analysis | Office | 2023 | 171 | 206 | $5,150 | $1,254 | 24.3% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 13 | 13 | $3,185 | $1,222 | 38.4% |
| 99490 | Chronic care management services, first 20 minutes of clinical staff time directed by health care professional, per calendar month | Office | 2023 | 13 | 26 | $2,210 | $1,203 | 54.4% |
| 20610 | Aspiration and/or injection of fluid from large joint | Office | 2023 | 19 | 22 | $4,750 | $1,166 | 24.5% |
| 77063 | Screening 3d breast mammography | Office | 2023 | 52 | 52 | $6,500 | $1,157 | 17.8% |
| 77080 | Dxa bone density measurement of hip, pelvis, spine | Office | 2023 | 32 | 32 | $6,848 | $1,155 | 16.9% |
| 71271 | Low dose ct scan of chest for lung cancer screening | Office | 2023 | 12 | 12 | $4,800 | $1,035 | 21.6% |
| 84153 | Psa (prostate specific antigen) measurement, total | Office | 2023 | 47 | 51 | $3,417 | $901.00 | 26.4% |
About Dr. Joseph Moran, M.D
Dr. Joseph Moran, M.D is a Internal Medicine healthcare provider based in Statesville, North Carolina. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 09/19/2005. The National Provider Identifier (NPI) number assigned to this provider is 1982699641.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Joseph Moran, M.D has received a total of $37,250 in payments from pharmaceutical and medical device companies, with $27,082 received in 2024. These payments were reported across 741 transactions from 55 companies. The most common payment nature is "" ($15,955).
As a Medicare-enrolled provider, Moran has provided services to 15,226 Medicare beneficiaries, totaling 28,295 services with total Medicare billing of $691,883. Data is available for 4 years (2020–2023), covering 234 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Location Statesville, NC
- Active Since 09/19/2005
- Last Updated 08/15/2023
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1982699641
Products in Payments
- DAVINCI XI (Device) $9,500
- Da Vinci Surgical System (Device) $2,333
- INNOVAMATRIX AC (Device) $915.97
- Ozempic (Drug) $623.83
- CHANTIX (Drug) $506.77
- ELIQUIS (Drug) $438.77
- TRADJENTA (Drug) $347.84
- Saxenda (Drug) $324.19
- Aimovig (Biological) $301.93
- FARXIGA (Drug) $258.21
- Victoza (Drug) $226.35
- Natesto (Drug) $222.35
- XARELTO (Drug) $213.24
- Rybelsus (Drug) $212.40
- Repatha (Biological) $193.87
- JANUVIA (Drug) $182.44
- TRULICITY (Drug) $175.35
- Prolia (Biological) $168.35
- Vascepa (Drug) $168.14
- Wegovy (Drug) $155.01
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Statesville
Mr. Menelaos Voulgaropoulos, M.d, M.D
Internal Medicine — Payments: $71,910
Internal Medicine $71,910
Bob Wodecki, Md, MD
Internal Medicine — Payments: $39,505
Internal Medicine $39,505
William White, Md, MD
Internal Medicine — Payments: $18,470
Internal Medicine $18,470
Debra Szostak-Wodecki, Md, MD
Internal Medicine — Payments: $14,967
Internal Medicine $14,967
Anita Misra, M.d, M.D
Internal Medicine — Payments: $11,249
Internal Medicine $11,249
John Nicholson, Md, MD
Internal Medicine — Payments: $8,900
Internal Medicine $8,900